Loading
ML
Mabpharm Ltd. - B Stock: price and insider trades · Hong Kong
Mabpharm Ltd. - B: what insiders have been doing
Mabpharm Ltd. - B has a thin disclosure history in our data (latest filing: 28 November 2023). New filings will appear here as soon as they are published. Source: insider filings from HKEX. Past trades are no guide to future returns.
Insider Decl.
5
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
1 ops. · all time
Fundamental score
Ranked 13,514 of 26,320 companies
50.7
score / 100
Value30
Quality71
FCF yld-1.1%
Earn yld2.7%
EV/EBITDA32.8x
ROE58%
Gross mgn89%
Net mgn8.8%
Debt/EBITDA4.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
HK$0.52
Analyst consensus
Income statement
RevenueHK$646.1M
Gross profitHK$573.7M89% margin
EBITDAHK$74.8M12% margin
Net incomeHK$57.1M11.1% margin
Valuation
PER (trailing)25.8x
P/Book9.3x
Beta0.60
Balance sheet & cash
Market capHK$2.1B
Total debtHK$326.7M
Free Cash Flow-HK$23.2M
Debt / Equity159%
Profitability & ownership
ROE58.5%
ROA2.0%
% insiders59.2%
% institutions18.0%
Last declaration on 28 November 2023
Declarations5 total
29,642,137 sharesShareXHKGHKEX:DA20231128E00440
2,227,000,000 sharesShareXHKGHKEX:DA20231128E00439
3,236,234 sharesShareXHKGHKEX:DA20231128E00441
29,642,137 sharesShareXHKGHKEX:DA20231128E00442
75,192 sharesShareXHKGHKEX:DA20230901E00286
5 of 5 declarations
About Mabpharm Ltd. - B
Mabpharm Ltd. is a company focused on drug development. It is listed on the Hong Kong Stock Exchange under the symbol XHKG.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
